Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AutoGenomics gets FDA approval for Infiniti Warfarin assay
Fareed Kureshy, president and CEO of AutoGenomics, said: “The FDA recently re- labeled warfarin stating that genetic testing may help optimize the use of the drug and lower
Fareed Kureshy, president and CEO of AutoGenomics, said: “The FDA recently re- labeled warfarin stating that genetic testing may help optimize the use of the drug and lower
The goal of this collaboration is to take the treasure trove of valuable information developed and collected by both companies over the years and make it accessible to
In March 2007, Cephalon has submitted the Effentora European new drug application for the treatment of breakthrough pain in adult cancer patients who are already receiving maintenance opioid
The establishment of Nihon Biobase was done within a very strict time frame of only three months. The new office, located in Shin Yokohama within the new Nisso
In this one-year, non-pivotal study, denosumab treatment achieved significantly greater bone mineral density (BMD) gains at the total hip, hip trochanter and distal radius compared with alendronate (Fosamax).
In the NAPA-2 clinical trial, the primary endpoint of 30-day open vascular surgery avoidance was achieved in 34.9% of patients receiving alfimeprase, 37.2% of patients receiving intra-thrombus (IT)
Tandem Labs will continue to operate under its existing name with its current employee and management structure, as a member of the Esoterix clinical trials group at LabCorp.
Stryker will be responsible for Avance Nerve Graft distribution services for nerve repairs in the upper extremities, lower extremities and brachial plexus. AxoGen will provide distribution services within
It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 600,000 shares. Credit Suisse Securities (USA) will be acting as the sole
Under terms of the agreement, iNova will have the exclusive right to market and sell Labopharm’s once-daily tramadol product in Australia. Labopharm will supply iNova with finished packaged